ArtiQ, a Belgium-based startup, was founded in early 2019 by four committed founders with expertise in respiratory medicine, medical devices, and artificial intelligence. The company's mission is to leverage novel technologies to bring value to all stakeholders in the respiratory setting including patients, doctors, the healthcare system, and industry. With a focus on the interpretation of pulmonary function tests and improving lung disease diagnostics, ArtiQ has developed an artificial intelligence-based medical software. This innovative approach has attracted attention and investment, with a €1.00M Seed Round investment led by KBC and Gemma Frisius Fund in July 2019. As a dynamic and innovative spin-off of the University of Leuven, ArtiQ aims to become the trusted partner of medical practitioners for the diagnosis, treatment, and follow-up of respiratory problems, positioning itself at the intersection of biotechnology, healthcare, and information technology.
